X

Webinar Resources

To launch the webinar platform without having to download software, please access using the Chrome browser.

ASCPT  Webinar presented by the Special Populations (SPO) Community and Regulatory Science (RS) Community
Title:  Pediatric Master Protocols: Clinical Pharmacology Challenges and Opportunities
Date and Time: Monday, October 7, 2019, 1:00 pm ET
Speakers and Panelists: Luna Musib, PhD, Elimika Pfuma Fletcher, PharmD, PhD, and Nita Seibel, MD
Moderators: Anuradha Ramamoorthy, PhD
Description: This special session will focus on opportunities, considerations and challenges related to pediatric master protocols. The speakers will discuss pharmacogenomic and other clinical pharmacology considerations for master protocols. Examples of pediatric master protocols will be highlighted. The pharmacogenomic discussion will highlight considerations for patient selection and treatment allocation based on molecular subsets of disease. The session will also include a moderated panel discussion, including a clinician involved in the NCI Pediatric MATCH trial.
Registration Link: 
https://register.gotowebinar.com/#register/4299107357330724867

ASCPT Members-Only Webinar presented by the Biologics Community
Title:  Development of Talimogene Laherparepvec, First FDA Approved Genetically Modified Oncolytic Virus: Perspectives of Clinical Pharmacology
Date and Time: Tuesday, October 29, 2019, 2:00 pm ET
Speakers and Panelists: Matt Hsu, PhD, Sumita Bhatta, MD, and Xiaofei Wang, PhD
Moderators: Yow-Ming Wang, PhD
Description: Talimogene laherparepvec is an oncolytic virus-based therapeutic product that is derived from herpes simplex virus type 1 (HSV-1). It has been genetically modified to efficiently replicate within tumors and to enhance systemic antitumor immune responses by producing the immune stimulatory protein granulocyte-macrophage colony-stimulating factor (GM-CSF). Clinical pharmacology program of talimogene laherparepvec was designed to characterize the kinetics of viral clearance through biodistribution in the blood and urine, shedding from injected tumors and exterior of the dressing, anti-HSV-1 seroconversion, and GM-CSF expression in tumor tissue and serum. This special presentation will provide an introduction of genetically modified products and regulatory advances in this field, as well as challenges and clinical pharmacology support of talimogene laherparepvec development pathway.
Registration Link: 
https://attendee.gotowebinar.com/register/2000518926673682691

Submit a Webinar Proposal

  • *
  • *
  • *






















  • *
  • *
  • *
  • *
  • *
  • *
  • *
Photo Gallery
Recent News
Contact Us